Status:
COMPLETED
Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients
Lead Sponsor:
Tungs' Taichung Metroharbour Hospital
Conditions:
Malnutrition
Oxidative Stress
Eligibility:
All Genders
20+ years
Brief Summary
Background YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 ...
Detailed Description
Study Design and Patients Patients This is a prospective observational study. The patients will be recruited from HD patients at dialysis units of Tungs Taichung Metroharbour Hospital, which is an ou...
Eligibility Criteria
Inclusion
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Exclusion
- heart failure
- infection
- cirrhosis
- respiratory disease
- nephrotic syndrome
- malignancy
- chronic liver disease
- severe inflammation
- None of the patients are receiving surgical operations or hospitalized in recent 3 months.
Key Trial Info
Start Date :
May 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT06206694
Start Date
May 2 2024
End Date
December 31 2024
Last Update
June 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan